Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study

Combining chemotherapy with immunotherapy improves the therapeutic outcome for first-line (1L) patients with advance nonsmall-cell lung cancer (NSCLC). Two cohorts of a phase 1b study (NCT02937116) aimed to evaluate the safety and efficacy of sintilimab, a PD-1 inhibitor, plus chemotherapy in 1L pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Haiping, Zheng, Yulong, Qian, Jiong, Mao, Chenyu, Xu, Xin, Li, Ning, Xiao, Cheng, Wang, Huan, Teng, Lisong, Zhou, Hui, Wang, Shuyan, Zhu, Donglei, Sun, Tao, Yu, Yingying, Guo, Wenying, Xu, Nong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Clinical Trial Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907015/
https://www.ncbi.nlm.nih.gov/pubmed/33070260
http://dx.doi.org/10.1007/s00262-020-02738-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7907015/
https://www.ncbi.nlm.nih.gov/pubmed/33070260
http://dx.doi.org/10.1007/s00262-020-02738-x

Ejemplares similares